INKINE PHARMACEUTICAL CO INC 4
4 · INKINE PHARMACEUTICAL CO INC · Filed Oct 4, 2005
Insider Transaction Report
Form 4
ROSE MARTIN
Exec VP for R&D
Transactions
- Disposition to Issuer
Common Stock
2005-09-30−20,040→ 0 total - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−250,000→ 0 totalExercise: $1.50Exp: 2009-02-28→ Common Stock (250,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−45,000→ 0 totalExercise: $7.66Exp: 2010-11-19→ Common Stock (45,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−20,000→ 0 totalExercise: $3.06Exp: 2010-01-13→ Common Stock (20,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−90,000→ 0 totalExercise: $1.05Exp: 2012-05-22→ Common Stock (90,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−40,000→ 0 totalExercise: $2.82Exp: 2013-06-01→ Common Stock (40,000 underlying) - Disposition to Issuer
Common Stock
2005-09-30−138,100→ 0 total - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−35,000→ 0 totalExercise: $3.56Exp: 2011-05-15→ Common Stock (35,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−22,500→ 0 totalExercise: $0.83Exp: 2011-09-30→ Common Stock (22,500 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−50,000→ 0 totalExercise: $2.96Exp: 2015-03-27→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to merger agreement between Salix Pharmaceuticals, Ltd. ("Salix) and InKine Pharmaceutical Company, Inc. As a result of the merger, the reporting person received 0.1737 share of Salix common stock for each share of InKine common stock.
- [F2]Consists of fully vested restricted shares of common stock disposed of pursuant to merger agreement between Salix Pharmaceuticals, Ltd. ("Salix) and InKine Pharmaceutical Company, Inc. As a result of the merger, the reporting person received 0.1737 shares of Salix common stock for each share of InKine common stock.
- [F3]All of the options described above were converted in the merger into options to purchase Salix common stock based on an exchange ratio of 0.1737. These options, which are fully vested, now represent the right to purchase 109,865 shares of Salix common stock at a weighted average exercise price of $12.43 per share.